Navigation Links
Advance Nanotech's Owlstone Announces First Pharmaceutical Industry Order
Date:3/12/2009

NEW YORK, March 12 /PRNewswire-FirstCall/ -- Advance Nanotech, Inc., (OTC Bulletin Board: AVNA), today announced that the Company's majority owned subsidiary, Owlstone Nanotech, Inc., has received an initial purchase order from Genzyme Corporation one of the world's leading biotechnology companies, for its Lonestar detection system. Bret Bader, CEO of Advance Nanotech, said, "As a result of our superior FAIMS based solution, we continue to make strong progress in unlocking the future revenue potential of significant strategic applications. We see this initial contract as a launching pad to further business development in the pharmaceutical industry."

There are numerous potential opportunities to apply Lonestar's high speed sensitive and selective detection capabilities in pharmaceutical manufacturing where there is a need to analyze solvent levels in the headspace of a process line. Owlstone's Lonestar is ideal for integration into pharmaceutical process lines to optimize manufacturing throughput and reduce costs.

Genzyme approached Owlstone with specific detection requirements for solvents that are difficult to identify at low concentrations with other products and technologies. During feasibility trials, Lonestar successfully demonstrated its capability to detect the analyte while meeting operational constraints for infield use.

Dylan Jones, Senior Manager Process Analytics at Genzyme said, "Genzyme is committed to finding medical treatments for people with serious diseases. We are pleased to invest in innovative technologies where we see opportunities to explore better ways of ensuring our patients get the quality of medication they require."

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown fro
'/>"/>

SOURCE Advance Nanotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AMDL, Inc. Enters Into Collaboration Agreement to Advance Development of Its AMDL DR-70 (FDP) Cancer Test
2. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
3. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
4. State-of-the-art electron microscope promises to aid major research advances
5. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
6. Advanced Life Sciences Receives Notice of Planned Cethromycin Review by FDA Advisory Committee
7. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
8. Genetic discovery could lead to advances in dental treatment
9. ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs
10. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
11. Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project ... the legal requirements around using controlled substances in pharmaceutical ... As their international operations expand and become increasingly complex, ... as a result of the first phase of the ...
(Date:1/22/2015)... PALO ALTO, Calif. , Jan. 22. 2015  Varian Medical ... equipment and software, has been honored for its commitment to ... most sustainable companies. Varian is the highest ranked healthcare equipment ... ranking, announced today during the World Economic Forum at ...
(Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Oct. 27 /Xinhua-PRNewswire/ -- Recently, China Green,Material ... Intellectual,Property Office for two patents for Industrialized ... and Industrialized Production,Method of Fully Biodegradable Edible ... applications have both obtained acceptance numbers,200810064592 and ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) today ... study,demonstrating that repeat administration with TRU-015 continues ... rheumatoid arthritis,(RA) signs and symptoms based on ... announced positive results following preliminary,analyses from a ...
... Inc. ("Carna"),announced on October 27, 2008, the signing ... ("SUBC"). Under the terms of this,Agreement, SUBC will ... China., With China,s emergence as a strong ... companies have now established,research and production facilities in ...
Cached Biology Technology:Patent Technologies Keep CGMT in a Leading Position in the Industry 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 2Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 3Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 4Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis 5Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
(Date:1/22/2015)... Report Issued by Small Cap IR. In 2011, Nilson Report,s ... at merchants on the leading payment cards rose to $135.3 ... and prepaid cards reached 6.54 billion.  Eight million credit card ... in 2012, and credit and debit card fraud resulted in ...
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... MD Researchers from The Johns Hopkins Medical Institutions ... immunohistochemistry to distinguish hydatidiform moles. The related report ... Analytic Validation of a Multiplex Short Tandem Repeat ... The Journal of Molecular Diagnostics . Molar ...
... of sediment cores indicates that biological and chemical changes occurring ... 200,000 years and likely are the result of human-caused climate ... of Colorado at Boulder. While environmental changes at ... be tightly linked with natural causes of climate change -- ...
... 20 Aware, Inc. (Nasdaq: AWRE ), a leading ... results for its third quarter ended September 30, 2009. ... Officer, said, "Earlier today, we announced an agreement to sell ... new fabless semiconductor company being spun out of Infineon. ...
Cached Biology News:Classifying molar pregnancy 2Arctic lake sediments show warming, unique ecological changes in recent decades 2Arctic lake sediments show warming, unique ecological changes in recent decades 3Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Normal sheep serum collected from healthy normal sheep...
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Biology Products: